The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.
Tecovirimat is the drug most commonly used to treat patients infected with the mpox virus. Unfortunately, it is sometimes ineffective against certain variants of the virus that have mutations in ...
The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox,” said Past ACTG Chair Judith Currier M.D., M.Sc. “There was considerable ...
Tecovirimat is the drug most commonly used to treat patients infected with the mpox virus. Unfortunately, it is sometimes ineffective against certain variants of the virus that have mutations in ...
NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating that tecovirimat did not ...
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback